Viking Therapeutics, Inc.
VKTX
Health Care
1
exclusion reason
1 theme
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
Viking Therapeutics develops metabolic and endocrine therapies. Its lead candidate VK2735 is a dual GLP-1/GIP receptor agonist for obesity available in both subcutaneous and oral formulations. Phase 2 results showed up to 14.7% body weight reduction after 13 weekly subcutaneous doses with no signs of plateau. The company completed enrollment in the Phase 3 VANQUISH-1 trial ahead of schedule and expects VANQUISH-2 enrollment completion in early 2026, with both trials evaluating 78 weeks of treatment. VK5211, a selective androgen receptor modulator, targets musculoskeletal conditions. Both drug candidates required extensive preclinical animal testing: VK2735's GLP-1/GIP dual agonism was characterized in rodent metabolic models evaluating weight loss, glucose tolerance, and food intake, while VK5211 underwent animal pharmacology and safety studies for muscle and bone endpoints mandated by FDA regulations.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.